

FINANCIAL TEAR SHEET

Corporate Profile

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient's own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

Primary IR Contact

Investor Contact

Email:

IR@adaptimmune.com

Stock Performance

ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	\$3.92
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$3.55
Market Cap	\$2,463,160,616
Rolling EPS	-1.02
PE Ratio	0
Shares Outstanding	628,357,300

Data as of 05/21/19 4:00 p.m. ET



Recent Headlines & Events

05/15/19

[Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products](#)

05/06/19

[Adaptimmune Reports First Quarter 2019 Financial Results](#)

05/06/19

[Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors](#)

There are currently no events scheduled.

SEC Filings

FILING DATE

FORM

Corporate Governance

[James Noble](#)

Chief Executive Officer

05/17/19	<u>4</u>	<u>Helen Tayton-Martin, PhD,</u> <u>MBA</u>	Chief Business Officer
05/15/19	<u>8-K</u>	<u>Rafael Amado, MD</u>	President Research and Development
05/06/19	<u>10-Q</u>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
05/06/19	<u>8-K</u>	<u>William (Bill) Bertrand</u>	Chief Operating Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.